How Netflix (And 14 Other Blue Chips) Got Its Groove Back

Here is a list of 15 companies that have turned their businesses around, led by Netflix, which is now humming along with profitability and a soaring stock price More 

Trade of the Day: Novartis (NVS)

This pharmaceutical stock has a history of holding steady in the storm. If selling continues today, it could make for an attractive entry. More 

Bulls vs. Bears: Can Biogen Keep Booming?

Biogen has been soaring on news of its recent drug approval, but the question remains when it can keep it up. Here are the bullish and bearish arguments. More 

India Drops Patent Bomb on Novartis

India's ruling on a Novartis patent draws a clear line of favor between generic drug companies and Big Pharma. More 

Novartis Loses Important Patent Battle

A long-running battle by Novartis to gain a patent for an updated cancer drug in India has been struck down by the country's supreme court. More 

The Best and Worst Mutual Funds of Q1 2013

Healthcare and Japanese stocks were among some of the hottest mutual fund flavors of the year's first quarter, while India and gold lagged behind. More 

FDA Approves New Biogen Drug to Treat MS

The Food and Drug Administration has approved Biogen Idec's new multiple sclerosis capsule, Tecfidera. More